Published in Trends Pharmacol Sci on June 15, 2007
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One (2008) 1.27
AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol (2012) 1.13
Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice. Circulation (2013) 1.01
A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics (2010) 0.97
Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology (2009) 0.93
Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis. J Neuroinflammation (2008) 0.87
Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture. Alzheimers Dement (2011) 0.82
The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. J Neural Transm (Vienna) (2011) 0.81
3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation. Am J Physiol Gastrointest Liver Physiol (2010) 0.78
Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. PLoS One (2016) 0.77
Simvastatin Results in a Dose-Dependent Toxic Effect on Spiral Ganglion Neurons in an In Vitro Organotypic Culture Assay. Biomed Res Int (2016) 0.75
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats. Neurol Sci (2015) 0.75
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol (2008) 7.35
Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol (2009) 6.96
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Regulation of miRNA expression during neural cell specification. Eur J Neurosci (2005) 5.27
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell (2010) 4.45
Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J (2006) 4.34
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
OSVZ progenitors of human and ferret neocortex are epithelial-like and expand by integrin signaling. Nat Neurosci (2010) 3.21
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci (2012) 2.90
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol (2008) 2.71
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity (2010) 2.54
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage (2011) 2.31
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2. Nat Cell Biol (2009) 2.12
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J (2005) 2.04
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain (2002) 2.02
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron (2005) 2.01
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci (2003) 1.95
Migration of monocytes after intracerebral injection at entorhinal cortex lesion site. J Leukoc Biol (2012) 1.93
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J Neurosci (2008) 1.85
Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol (2007) 1.85
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
A mechanism for neurodegeneration induced by group B streptococci through activation of the TLR2/MyD88 pathway in microglia. J Immunol (2006) 1.76
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Mutations in mouse Aspm (abnormal spindle-like microcephaly associated) cause not only microcephaly but also major defects in the germline. Proc Natl Acad Sci U S A (2010) 1.76
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain (2003) 1.75
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med (2011) 1.72
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol (2013) 1.69
The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci (2006) 1.68
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Boxing-acute complications and late sequelae: from concussion to dementia. Dtsch Arztebl Int (2010) 1.59
CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci (2004) 1.57
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Glatiramer acetate: evidence for a dual mechanism of action. J Neurol (2008) 1.49
Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem (2003) 1.48
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med (2003) 1.47
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47